Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $12,835.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 500 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $25.67, for a total value of $12,835.00. Following the sale, the director now directly owns 72,909 shares in the company, valued at $1,871,574.03. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Amphastar Pharmaceuticals Trading Down 0.6%

Amphastar Pharmaceuticals stock traded down $0.15 during mid-day trading on Wednesday, hitting $25.86. The company's stock had a trading volume of 395,476 shares, compared to its average volume of 485,141. The company has a 50 day moving average of $24.75 and a 200-day moving average of $31.84. The stock has a market cap of $1.22 billion, a PE ratio of 8.62, a P/E/G ratio of 2.19 and a beta of 0.78. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC grew its position in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after acquiring an additional 493 shares during the last quarter. Signaturefd LLC increased its stake in shares of Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after buying an additional 520 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Amphastar Pharmaceuticals by 806.5% during the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after buying an additional 871 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at $38,000. Finally, Tower Research Capital LLC TRC boosted its position in Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares in the last quarter. Institutional investors own 65.09% of the company's stock.

Analysts Set New Price Targets

AMPH has been the topic of several recent research reports. Piper Sandler decreased their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Wells Fargo & Company decreased their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. JPMorgan Chase & Co. restated a "neutral" rating and set a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.